| 2933.39.61 | | Products described in additional U.S. note 3 to section VI | | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2933.49.60 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2933.59.70 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2933.79.04 | 00 | 2,5-Dihydro-3,6-diphenylpyrrolo-(3,4-c)- pyrrole-1,4-dione | kg | Free | | 15.4￠/kg + 52% |
| 2933.79.08 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2933.99.02 | 00 | 2-[4-[(6-Chloro-2-quinoxalinyl)oxy]phenoxy]- propionic acid, ethyl ester; and O,O-Dimethyl-S-[(4-oxo-1,2,3-benzotri- azin-3-(4H)-yl)methyl]phosphorodithioate | kg | Free | | 15.4￠/kg + 64.5% |
| 2933.99.79 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.10.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.20.40 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.30.43 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2934.99.39 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 52% |
| 2935.00.75 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,L,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 57.5% |
| 2937.23.25 | 00 | Estradiol benzoate; and Estradiol cyclopentylpropionate (Estradiol cypionate) | g | Free | | 15.4￠/kg + 49% |
| 2937.29.10 | 00 | Desonide; and Nandrolone phenproprionate | g | Free | | 15.4￠/kg + 49% |
| 2942.00.10 | 00 | Products described in additional U.S. note 3 to section VI | kg | 6.5% | Free (A+,AU,BH, CA,CL,D,E,IL,J, JO,K,MA,MX, P) 2.9% (SG) | 15.4￠/kg + 46.5% |
| 3001 | | Glands and other organs for organotherapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organotherapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included: | | | | |
| 3001.20.00 | 00 | Extracts of glands or other organs or of their secretions | kg | Free | | 10% |
| 3002 | | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products: | | | | |
| 3002.10.01 | | Antisera and other blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes | | Free | | Free |
| 3002.90.51 | 20 | Antiallergenic preparations | kg | | | |
| 3004 | | Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale: | | | | |
| 3004.10.10 | 45 | Combination antibiotics | kg | | | |
| 3004.10.50 | 45 | Combination antibiotics | kg | | | |
| 3004.20.00 | 20 | Erythromycin, singles or in combination with other antibiotics | kg | | | |
| 3004.20.00 | 30 | Tetracycline, singles or in combination with other antibiotics | kg | | | |
